About Rhythm Pharmaceuticals, Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company’s lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Address: 222 Berkeley Street, Boston, MA, United States, 02116
Rhythm Pharmaceuticals, Inc News and around…
Latest news about Rhythm Pharmaceuticals, Inc (RYTM) common stock and company :
Analysts have provided the following ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) within the last quarter: ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips You've heard the adage "buy the dip," but not all dips are made equal. There are several strategies for finding worthwhile discounted stocks. The post 3 Stocks to Buy the Dip Now appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
Here at CryptocurrenciesChannel. om, we find it interesting to track various ETF and stock prices versus various digital assets over time.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that on May 3, 2022, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 50,730 shares of its common stock to 10 new employees, consisting of inducement stock options to purchase an aggregate of 16,
During Thursday, 351 stocks hit new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest ...
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 5:20 p.m. PT (8:20 p.m. ET) in Las Vegas, NV. A live audio webcast of the f
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Acadia Announces FDA AdComm ...
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -7.14% and 38.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its Q1 earnings results on Tuesday, May 3, 2022 at 08:00 AM. Here's what ...
-- Patient identification and physician engagement ongoing in preparation for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial patients treated with IMCIVREE® (setmelanotide) in France under paid early access program -- -- First patients enrolled in Phase 3 EMANATE trial and Phase 2 DAYBREAK trial -- -- Multiple abstracts accepted for presentation at ENDO 2022 -- -- Management to host conference call today at 8:30 a.m. ET -- BOSTON, May
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its ...
-- New data show setmelanotide treatment led to clinically meaningful improvements in lipid parameters, without affecting blood pressure or heart rate in patients with BBS -- -- Additional posters include data from pediatric and adolescent patients enrolled in Phase 3 trial in BBS and qualitative data regarding the impact of hyperphagia on BBS patients and their caregivers -- -- Also presenting cumulative safety data demonstrating setmelanotide was generally safe and well tolerated across 561 pa
Rhythm Pharmaceuticals (NASDAQ:RYTM) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings ...
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 3, 2022 to report its first quarter 2022 financial results and provide a corporate update. To access the live conference call, please dial (866) 374-5140 (domestic) or (404) 4
Rhythm Pharmaceuticals, Inc. (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals (RYTM) modifies the design of its two genetic obesity disorder studies to focus on rare patients, thus reducing the targeted population size. RYTM expects to save costs in the process.
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies ...
Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 32.4% to $7.43 during Wednesday's regular session. Sunshine ...
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor ...
Rhythm Pharmaceuticals Inc(NASDAQ: RYTM)will modify itsPhase 3 EMANATE and ongoing Phase 2 DAYBREAK trials of ...
– Phase 3 EMANATE trial to focus on rare patient populations with highest likelihood for success – – First patient enrolled in EMANATE – – Ongoing Phase 2 DAYBREAK trial to focus initially on 10 genes with strongest relevance to the MC4R pathway – – Trial and other program changes extend cash runway into 4Q2023 – BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Riot Blockchain Inc (RIOT), where a total volume of 62,117 contracts has been traded thus far today, a contract volume which is representative of approximately 6.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 72.8% of RIOT's average daily trading volume over the past month, of 8.5 million shares..
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in MongoDB Inc (MDB), where a total volume of 8,612 contracts has been traded thus far today, a contract volume which is representative of approximately 861,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 60% of MDB's average daily trading volume over the past month, of 1.4 million shares..
Benzinga Pro data, Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q4 sales of $1.82 million. Earnings fell to a loss of $42.87 million, ...
Wren Appoints Bart Henderson as Chief Executive Officer
BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the Cowen & Co. 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 10:30 a.m. ET. A live audio webcast of the fireside chat will be avail
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's ...
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 15% and 6.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
-- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial sales of IMCIVREE in Germany and France expected in 2Q2022 – -- Enrollment completed in Phase 2 trial evaluating setmelanotide in patients with hypothalamic obesity -- -- IMCIVREE fourth quarter sales of $1.8M and 2021 sales of $3.2M – -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceutica
Rhythm Pharmaceuticals, Inc (RYTM) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
